CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
SHARE THIS ARTICLE
Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit
ONTE VEDRA, Fla., Nov. 12, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presentation at the November 2024 European Association for Cardio-thoracic Surgery (EACTS) Mechanical Circulatory Support Summit that featured tecarfarin historical data and Cadrenal's proposed clinical trial protocol to evaluate tecarfarin versus warfarin in patients with the Abbott HeartMate3 (HM3) left ventricular assist device (LVAD).
The presentation, titled Tecarfarin and Hemocompatibility with LVAD Therapy (TECH-LVAD), took place in Prague, Czech Republic and outlined Cadrenal's proposed clinical trial protocol recently submitted to the U.S. Food and Drug (FDA). Dr. Mandeep R. Mehra, who holds the William Harvey Chair in Advanced Cardiovascular Medicine and is Executive Director, Center for Advanced Heart Disease, Brigham and Women's Hospital, developed and delivered the TECH-LVAD presentation. In the presentation Dr. Mehra highlighted data from past trials demonstrating the inverse relationship between bleeding rates and time in therapeutic range (TTR) for HM3 patients, and evidence from prior studies indicating tecarfarin's potential ability to improve TTR. He included data from a trial in end-stage kidney disease (ESKD) patients showing that ESKD does not alter tecarfarin exposure while warfarin exposure is increased, explaining that this is one of the critical differentiators for tecarfarin because many LVAD patients have kidney impairment.
Dr. Mehra, who also chaired Abbott's ARIES-HM3 study in LVAD patients and is a Professor of Medicine, Harvard University, commented, "In the proposed TECH-LVAD trial, we plan to study a much-needed VKA option with the expectation of reducing bleeding events that accompany use of the HM3 LVAD in advanced heart failure. Tecarfarin could potentially be an important therapy for patients with LVADs who all require chronic anticoagulation."
"As our team progresses discussions with the FDA and Abbott about a tecarfarin study in LVAD patients, increasing tecarfarin data visibility will help us to continue accelerating our development as we plan for investigator outreach and patient recruitment for our tecarfarin trial," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, more effective chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds, and deaths than warfarin, the most commonly used anticoagulant for these patients, despite its prevalent adverse events, drug-to-drug interactions, and frequent dosing changes. Cadrenal is focused on evaluating tecarfarin's superiority to warfarin in these patients where direct oral anticoagulants (DOACs) are not recommended in the treatment guidelines of leading cardiology associations. Tecarfarin received an orphan drug designation for advanced heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is opportunistically planning pivotal clinical trials and pursuing clinical and commercial partnerships to advance tecarfarin. The company's plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. Visit www.cadrenal.com to learn more.
Safe Harbor Statement
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding our planned pivotal trial to evaluate tecarfarin's effectiveness for LVAD patients, tecarfarin's potential ability to improve TTR; the plan to study a much-needed VKA option with the expectation to reduce bleeding events that accompany use of the HM3 LVAD in advanced heart failure; tecarfarin potentially being an important therapy for patients with LVADs who all require chronic anticoagulation and advancing the visibility of tecarfarin data helping to continue to accelerate the Company's development as it plans for investigator outreach and patient recruitment for its tecarfarin trial. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to improve TTR and anticoagulation treatment in patients, the ability of the Company to advance tecarfarin with patients with left ventricular assist devices (LVADs) and those with ESKD with AFib, the collaborative efforts with Abbott being successful and the other risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more information, please contact:
SOURCE Cadrenal Therapeutics, Inc.
Disclaimer
Effective Date: [August, 2024]
This website/newsletter is owned, operated, and edited by Relqo Media LLC. Any wording found in this email or disclaimer referencing "I," "we," "our," or "Relqo Media" refers to Relqo Media LLC. This webpage/newsletter is a paid advertisement, not a recommendation or an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website, you agree to the terms of our disclaimer, which are subject to change at any time.
We are not registered or licensed in any jurisdiction to provide investing advice or any advisory or consultancy services, and are therefore unqualified to give investment recommendations. Always conduct your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve as a starting point to conduct your own research and consult with a licensed professional regarding the companies profiled and discussed.
Conduct your own research. Companies with a low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences issues with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data.
This publication, its owners, and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, potentially impacting share prices. If we own any shares, we will list the relevant stock information and the number of shares here. Relqo Media LLC's business model is to receive financial compensation to promote public companies.
Purpose
These websites, social media accounts, and all associated content are provided for informational and entertainment purposes only. Relqo Media LLC engages in marketing, advertising, and brand awareness for small-cap public companies. The content, including articles, emails, tweets, and other communications across our platforms, is classified as paid advertisements and should not be considered an offer, recommendation, or solicitation to buy or sell securities. Readers and users should not rely on the information provided as a basis for making investment decisions.
Compensation Disclosure
Relqo Media LLC is compensated for its promotional services by Penzance LLC, and this compensation may include cash payments, stock options, or other financial consideration from the companies we feature. The compensation received directly impacts the content presented on our platforms and creates a significant conflict of interest.
Cadrenal Therapeutics: Relqo Media LLC has been compensated $30,000 per week since August 8, 2024, to run a marketing campaign for Cadrenal Therapeutics. This payment will continue until May 1st, 2025, bringing the total compensation to seven hundred eighty thousand dollars.
NeoVolta Inc: Relqo Media LLC has been compensated four hundred thousand dollars starting November 11, 2024, to run a marketing campaign for NeoVolta Inc. This payment will continue until March 31, 2025. Compensation represents a major conflict of interest in our ability to remain unbiased. Therefore, this communication should be viewed as a commercial advertisement only.
We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates may wish to liquidate shares of the profiled company at or near the time you receive this communication, which could negatively impact share prices. Any non-compensated alerts are purely for the purpose of expanding our database for future financially compensated investor relations efforts. Frequently, companies profiled in our alerts may experience a significant increase in volume and share price during investor relations marketing, which may decline as soon as the marketing ceases.
Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed.
The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way to ensure its accuracy. Furthermore, Relqo Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. While independent writers' works are reviewed and edited before publication, errors or omissions may occur. You should assume all information in our communications is incorrect until you verify it yourself and are encouraged never to invest based solely on the information contained in our communications.
The information in this disclaimer is subject to change at any time without notice.
Stockverse Legal Disclaimer
Earnings & Performance Disclaimer
Stockverse provides stock market data, research tools, AI-generated insights, and other financial information strictly for educational and informational purposes.
No Guarantee of Future Performance
The past performance of any stock, security, or investment strategy does not guarantee future results. Stock markets are inherently volatile, and returns are unpredictable.
Investment Risks
Investing in stocks, securities, and financial markets carries substantial risk, including the risk of total loss of capital. Users should perform independent due diligence before making investment decisions.
No Financial Advice
Stockverse does not provide financial, investment, tax, or legal advice. Any information, data, or AI-generated insights should not be considered personalized financial advice. Users should consult a licensed financial professional before making any trading or investment decisions.
AI & Data Disclaimer
Stockverse integrates artificial intelligence (AI) technology (Stockverse GPT) and third-party financial data providers to generate stock insights and market analysis.
AI Limitations & Potential Errors
Stockverse GPT is powered by OpenAI and third-party data sources. While it provides AI-driven stock analysis, it can generate inaccurate, outdated, or misleading information. AI predictions and insights are not a substitute for professional financial analysis.
Delayed & Inaccurate Data
Stock market data displayed on Stockverse may be delayed, incomplete, or inaccurate due to exchange rules, provider limitations, or data outages. Stockverse does not guarantee the accuracy, reliability, or completeness of any financial data provided.
User Responsibility
Users acknowledge that Stockverse GPT and AI-generated insights should not be relied upon for making investment decisions. All trading and financial actions are taken at the user's sole discretion and risk.
Limitation of Liability
By using Stockverse, you acknowledge and agree that:
No Liability for Financial Losses
Stockverse, its owners, affiliates, partners, and employees shall not be liable for any direct, indirect, incidental, consequential, or financial losses incurred due to reliance on data, AI-generated insights, stock recommendations, or market trends displayed on this platform.
No Warranties
Stockverse makes no warranties or representations, express or implied, regarding the accuracy, reliability, or completeness of any content provided. All information is provided "as is" and "as available."
Third-Party Data & External Links
Stockverse may link to third-party content, stock exchanges, brokers, or news sources. We do not endorse, control, or assume responsibility for the accuracy or reliability of external websites or third-party data feeds.
Use at Your Own Risk
By using Stockverse, you acknowledge that all investment decisions are made solely at your own risk, and you release Stockverse from any and all liability associated with financial losses.
Governing Law & Dispute Resolution
Jurisdiction & Applicable Law
This Agreement and any disputes arising out of or relating to Stockverse shall be governed by and construed under the laws of the State of Wyoming, without regard to conflict of law principles.
Binding Arbitration
Any disputes, claims, or controversies arising out of or related to the use of Stockverse shall be exclusively resolved through binding arbitration in Wyoming, in accordance with the rules of the American Arbitration Association (AAA).
Waiver of Class Action & Jury Trial
By using Stockverse, you agree to waive any right to participate in a class action lawsuit or jury trial against Stockverse, its owners, affiliates, and representatives.
Intellectual Property Rights
Ownership of Content
All content, design elements, trademarks, stock analysis, AI-generated insights, and proprietary data displayed on Stockverse are owned by Stockverse Holdings LLC and protected under U.S. and international copyright and intellectual property laws.
Restrictions on Use
Users may not copy, modify, distribute, sell, or republish any Stockverse content, AI-generated insights, or proprietary tools without explicit written permission from Stockverse Holdings LLC.
AI-Generated Content & Licensing
AI-generated insights, trade signals, and stock analysis provided by Stockverse GPT are proprietary and cannot be resold, republished, or distributed for commercial use without express authorization.
DMCA & Copyright Violations
Any unauthorized reproduction or use of Stockverse content may result in legal action under the Digital Millennium Copyright Act (DMCA) or applicable intellectual property laws.
Acceptance of Terms
By accessing and using Stockverse, you acknowledge that you have read, understood, and agreed to this disclaimer. If you do not agree with any part of this disclaimer, you must discontinue use of this platform immediately.
For any legal inquiries or compliance concerns, please contact:
📧 support@stockverse.com🌐 Stockverse.com